{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:14:14Z","timestamp":1764656054953,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["DFG KO 2155\/6-1"],"award-info":[{"award-number":["DFG KO 2155\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00277-019-03836-2","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T06:04:15Z","timestamp":1574229855000},"page":"2703-2709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-6353","authenticated-orcid":false,"given":"Martin","family":"Kirschner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bornemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Kricheldorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Skorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"6","key":"3836_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kr\u00f6ger N, Mesa R, McMullin M, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European LeukemiaNet (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770","journal-title":"J Clin Oncol"},{"issue":"4","key":"3836_CR2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure R, Giles F, Kantarjian HM (2006) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108(4):1158\u20131164","journal-title":"Blood"},{"issue":"12","key":"3836_CR3","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119(12):2721\u20132730","journal-title":"Blood"},{"issue":"7","key":"3836_CR4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472\u20131477","journal-title":"Leukemia"},{"issue":"2","key":"3836_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMe0903044","volume":"361","author":"JD Iglehart","year":"2009","unstructured":"Iglehart JD, Silver DP (2009) Synthetic lethality--a new direction in cancer-drug development. N Engl J Med 361(2):189\u2013191","journal-title":"N Engl J Med"},{"issue":"2","key":"3836_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM199801083380211","volume":"338","author":"SH Friend","year":"1998","unstructured":"Friend SH, Oliff A (1998) Emerging uses for genomic information in drug discovery. N Engl J Med 338(2):125\u2013126","journal-title":"N Engl J Med"},{"issue":"2","key":"3836_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-5193(03)00087-0","volume":"223","author":"A Kamb","year":"2003","unstructured":"Kamb A (2003) Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancer. J Theor Biol 223(2):205\u2013213","journal-title":"J Theor Biol"},{"issue":"9","key":"3836_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689\u2013698","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3836_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852\u2013861","journal-title":"Lancet Oncol"},{"issue":"11","key":"3836_CR10","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1182\/blood-2002-10-3011","volume":"101","author":"E Deutsch","year":"2003","unstructured":"Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J (2003) Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101(11):4583\u20134588","journal-title":"Blood"},{"issue":"7","key":"3836_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","volume":"122","author":"K Cramer-Morales","year":"2013","unstructured":"Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D et al (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122(7):1293\u20131304","journal-title":"Blood"},{"issue":"26","key":"3836_CR12","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","volume":"130","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M et al (2017) Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood 130(26):2848\u20132859","journal-title":"Blood"},{"issue":"20","key":"3836_CR13","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M et al (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121(20):4175\u20134183","journal-title":"Blood"},{"issue":"10","key":"3836_CR14","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1128\/MCB.26.10.3935-3941.2006","volume":"26","author":"N Puebla-Osorio","year":"2006","unstructured":"Puebla-Osorio N, Lacey DB, Alt FW, Zhu C (2006) Early embryonic lethality due to targeted inactivation of DNA ligase III. Mol Cell Biol 26(10):3935\u20133941","journal-title":"Mol Cell Biol"},{"issue":"10","key":"3836_CR15","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1158\/0008-5472.CAN-04-3055","volume":"65","author":"H Wang","year":"2005","unstructured":"Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F, Iliakis G (2005) DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res 65(10):4020\u20134030","journal-title":"Cancer Res"},{"issue":"14","key":"3836_CR16","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/onc.2012.203","volume":"32","author":"LA Tobin","year":"2013","unstructured":"Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV (2013) Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 32(14):1784\u20131793","journal-title":"Oncogene"},{"issue":"12","key":"3836_CR17","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","volume":"104","author":"MO Nowicki","year":"2004","unstructured":"Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T (2004) BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104(12):3746\u20133753","journal-title":"Blood"},{"issue":"8","key":"3836_CR18","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","volume":"68","author":"T Stoklosa","year":"2008","unstructured":"Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J et al (2008) BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 68(8):2576\u20132580","journal-title":"Cancer Res"},{"issue":"4","key":"3836_CR19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2010-09-307256","volume":"118","author":"A Slupianek","year":"2011","unstructured":"Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T (2011) Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood 118(4):1062\u20131068","journal-title":"Blood"},{"issue":"4","key":"3836_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/em.22269","volume":"60","author":"N Ding","year":"2019","unstructured":"Ding N, Miller SA, Savant SS, O'Hagan HM (2019) JAK2 regulates mismatch repair protein-mediated epigenetic alterations in response to oxidative damage. Environ Mol Mutagen 60(4):308\u2013319","journal-title":"Environ Mol Mutagen"},{"issue":"6","key":"3836_CR21","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/nar\/gkt076","volume":"41","author":"GL Dianov","year":"2013","unstructured":"Dianov GL, Hubscher U (2013) Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res 41(6):3483\u20133490","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3836_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","volume":"27","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27(3):247\u2013254","journal-title":"Nat Genet"},{"issue":"1","key":"3836_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","volume":"83","author":"N Gangat","year":"2009","unstructured":"Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP (2009) Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol 83(1):17\u201321","journal-title":"Eur J Haematol"},{"issue":"9","key":"3836_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","volume":"102","author":"G Tang","year":"2017","unstructured":"Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE (2017) Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 102(9):1511\u20131518","journal-title":"Haematologica"},{"issue":"2","key":"3836_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/BF02981937","volume":"73","author":"T Okamura","year":"2001","unstructured":"Okamura T, Kinukawa N, Niho Y, Mizoguchi H (2001) Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73(2):194\u2013198","journal-title":"Int J Hematol"},{"issue":"4","key":"3836_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00277-004-0977-1","volume":"84","author":"U Bacher","year":"2005","unstructured":"Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C (2005) Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84(4):250\u2013257","journal-title":"Ann Hematol"},{"issue":"2","key":"3836_CR27","first-page":"107","volume":"4","author":"NR Singh","year":"2015","unstructured":"Singh NR (2015) Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis. Transl Pediatr 4(2):107\u2013115","journal-title":"Transl Pediatr"},{"issue":"4","key":"3836_CR28","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","volume":"112","author":"I Plo","year":"2008","unstructured":"Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL, Wiesmuller L, Vainchenker W (2008) JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112(4):1402\u20131412","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03836-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:25:24Z","timestamp":1605745524000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03836-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3836"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03836-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"THB: Consultancy: Novartis, Pfizer, Janssen, Merck; research funding: Novartis, Pfizer. SK: reports funding from Novartis, Bristol-Myers Squibb and Janssen, as well as consultancy, honoraria, and travel support from Novartis, Incyte, Ariad, Bristol-Myers Squibb, AOP, CTI, Pfizer, Celgene, and Shire. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}